



The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells

Soshi Kusunoki^a, Kiyoko Kato^{a,*}, Kouichi Tabu^b, Tetsunori Inagaki^a, Hitomi Okabe^a, Hiroshi Kaneda^a, Shin Suga^a, Yasuhisa Terao^a, Tetsuya Taga^b, Satoru Takeda^a

^a Department of Obstetrics and Gynecology, Faculty of Medicine, Juntendo University, Hongo 2-1-1, Bunkyo-ku, 113-8431, Japan

^b Department of Stem Cell Regulation, Medical Research Institute, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, 113-8510, Japan

HIGHLIGHTS

- Salinomycin reduced the level of fibronectin expression, which was enhanced in endometrial cancer stem cells.
- Salinomycin induced apoptosis and inhibited Wnt signaling.
- Salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of endometrial cancer stem cells.

ARTICLE INFO

Article history:
Received 24 August 2012
Accepted 5 March 2013
Available online xxx

Keywords:
Endometrial cancer
Cancer stem cell
Side-population cells
Salinomycin
Fibronectin

ABSTRACT

Goals. We previously demonstrated that side-population (SP) cells in human endometrial cancer cells (Hec1 cells) and in rat endometrial cells expressing oncogenic human K-Ras protein (RK12V cells) have features of cancer stem cells (CSCs). Hec1-SP cells showed enhanced migration and the potential to differentiate into the mesenchymal cell lineage. In this study, we analyzed the association of the epithelial–mesenchymal transition (EMT) with the properties of these endometrial CSCs. We also assessed the effects of salinomycin (a compound with EMT-specific toxicity) on the proliferative capacity, migration and invasiveness of these endometrial CSCs using Hec1-SP cells.

Method. We performed microarray expression analysis to screen for up-regulated genes in CSCs using a set of RK12V-SP cells and -non-SP(NSP) cells and used the Metacore package to identify the Gene GO pathway MAPs involved in the up-regulated genes. To analyze their association with EMT, the expression of several EMT associated genes in Hec1-SP cells was investigated by real time PCR and compared with that in Hec1-NSP cells. We assessed the expression of *BAX*, *BCL2*, *LEF1*, *cyclinD* and *fibronectin* by real time PCR. We also evaluated the viabilities, migration and invasive activities, and tumorigenicities of these SP cells and NSP cells in the presence or absence of salinomycin.

Results. We demonstrated that i) EMT processes were observed in both RK12V-SP cells and Hec1-SP cells, ii) the level of *fibronectin* was enhanced in Hec1-SP cells and salinomycin reduced the level of *fibronectin* expression, iii) salinomycin induced apoptosis and inhibited Wnt signaling, and iv) salinomycin inhibited the proliferation, migration, invasiveness and tumorigenicity of these SP cells.

Conclusion. This is the first report of an inhibitory effect of salinomycin on the properties of endometrial CSCs.

© 2013 Elsevier Inc. All rights reserved.

Introduction

Stem cells have a marked self-renewal capacity and are pluripotent. They can be identified in embryonic tissues as well as in normal adult tissues. The existence of cancer stem-like cells (CSCs) has been proposed and CSCs have been identified in leukemia and several solid

tumors [1–3]. The properties of CSCs are as follows: i) they possess self-renewal capacity, ii) they can produce progeny cells, iii) they constitute a small minority of neoplastic cells within a tumor, and iv) they possess the developmental potential for expression of multiple specific markers [4]. CSCs are resistant to current cancer treatment, resulting in an increased risk of recurrence.

Side-population (SP) cells are enriched in stem cells and have been isolated and characterized, using fluorescence-activated cell sorting (FACS). The methodology is based on the cells' ability to reduce the intracellular concentration of the fluorescent dye Hoechst 33342 [5]. The identification of SP cells is associated with a high

* Corresponding author at: Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan. Fax: +81 92 642 5414.

E-mail address: kkato@med.kyushu-u.ac.jp (K. Kato).

expression level of the ATP-binding cassette transporter protein ABCG2/BCRP1. The ATP-binding-cassette (ABC) transporters represent the largest family of transmembrane proteins capable of exporting a wide variety of molecules and structurally unrelated chemotherapeutic drugs from the cytosol. These proteins confer multidrug resistance to CSCs [6,7].

We isolated and characterized SP cells present in human endometrial cancer cells (Hec1 cells) and in rat endometrial cells expressing oncogenic human K-Ras protein (RK12V cells). The SP cells showed reduced expression levels of differentiation markers, long-term proliferative capacity of the cell cultures, self-renewal capacity, enhanced tumorigenicity, and enhanced migration. These findings demonstrate that SP cells have features of CSCs, including the potential to differentiate into the mesenchymal cell lineage [8].

The epithelial–mesenchymal transition (EMT) occurs during normal early embryonic development. This program allows a polarized epithelial cell, which normally interacts with the basement membrane via its basal surface, to undergo multiple biochemical changes that enable it to assume a mesenchymal cell phenotype, which includes enhanced migratory capacity and invasiveness [9]. EMT is also a key developmental program that is often activated during cancer invasion and metastasis. The EMT program enables cancer cells to disseminate from a primary tumor by losing epithelial characteristics and acquiring a mesenchymal phenotype. Mani et al. have reported a direct link between EMT and the gain of epithelial stem cell properties [10]. Human breast cancer stem cells express Snail and Twist, EMT-inducing transcription factors. When their expression is elevated, the size of the stem cell population is increased and expression levels of mesenchymal markers fibronectin and vimentin are enhanced [10]. Thus, EMT promotes the generation of cancer stem cells.

Salinomycin is a selective inhibitor of CSCs [11]. Salinomycin is an antibacterial and cocciidiostatic therapeutic drug. It has been shown to kill breast cancer stem cells in mice at least 100-times more effectively than the commonly used anti-cancer drug paclitaxel. Although several studies demonstrate that salinomycin has an inhibitory effect on proliferation of CSCs, the effects of salinomycin on the properties of endometrial CSCs are unclear.

In this study, we used Hec1-SP cells and RK12V-SP cells to analyze the association of EMT with the properties of endometrial CSCs and the effects of salinomycin on the proliferative capacity, migration and invasiveness of endometrial CSCs.

111 Materials and methods

112 Cell lines and cell culture

113 An endometrial cancer cell line (Hec-1) and a rat endometrial cell
114 line (RENT4) were used in the present study. The Hec-1 cell line was
115 established by Kuramoto et al. from explants of adenocarcinoma of
116 human endometrium [12] and it was a gift from Dr. Kuramoto. RENT4
117 cells were established by Wiehle et al. [13] and obtained from the Euro-
118 pean Collection of Cell Cultures (ECACC). Both cell lines were authenti-
119 cated by Takara Bio Inc. using the short tandem repeat (STR) DNA
120 profiling. The STR profiles of Hec-1 cells were matched to their original
121 profiles. Interspecies contamination was ruled out by the STR profiles in
122 both cell lines. Both cell lines were cultured at 37 °C in Dulbecco's
123 Modified Eagle's Medium (DMEM) + 10% fetal bovine serum (FBS) +
124 100 U/mL penicillin, and 100 µg/mL streptomycin.

125 Isolation of SP cells

126 To identify and isolate Hec1 SP cells, the cells were dislodged from
127 the culture dishes with trypsin and EDTA, washed, and suspended at a
128 concentration of 1×10^6 cells/mL in DMEM containing 10% FBS. The
129 cells were then labeled in the same medium at 37 °C for 90 min
130 with 2.5 µg/mL Hoechst 33342 dye (Molecular Probes, Eugene, OR),

either alone or in combination with 50 µmol/L verapamil (Sigma- 131
Aldrich). Finally, the cells were counterstained with 1 µg/mL propidium 132
iodide (PI) to label dead cells. The cells were then analyzed in a FACS 133
Vantage fluorescence-activated cell sorter (BD Biosciences, San Jose, 134
CA) using dual wavelength analysis (blue, 424–444 nm; red, 675 nm) 135
after excitation with 350 nm UV light. PI-positive dead cells were ex- 136
cluded from the analysis. 137

The SP cells were separated by FACS from the non-SP (NSP) cells and 138
both fractions were seeded in a mesenchymal stem cell maintenance 139
medium (MF medium; Toyobo, Osaka, Japan) containing 10% FBS on 140
collagen-coated 24-well plates (2 cm²) (Iwaki, Funabashi, Japan). The 141
cells were cultured for two to four weeks. The cells were then trans- 142
ferred to collagen-coated plates (60 mm). 143

144 RNA isolation

145 RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, 146
Germany) according to the manufacturer's instructions.

147 Real time quantitative PCR analysis

148 Real time PCR was carried out using a 7300 Real Time PCR System 149
with SDS RQ Study software (Applied Biosystems). cDNA templates 150
were combined with SYBER Green premix with Rox (Takara Bio) to 151
perform quantitative-PCR reactions. Primers used in this study are 152
shown in Supplementary Table 1. Reactions were carried out for 153
1 cycle at 94 °C for 5 min; 40 cycles at 94 °C for 30 s, 59 °C for 30 s 154
and 72 °C for 30 s; 1 cycle at 94 °C for 1 min; and 1 cycle at 55 °C 155
for 30 s. The transcript level of each specific gene was normalized to 156
GAPDH amplification.

157 In vitro scratch assay

158 The SP and NSP cells were cultured on 24-well plates in complete 159
medium. Upon reaching confluence, the medium was replaced with 160
conditioned medium DMEM containing 1% FBS in the presence or ab- 161
sence of salinomycin (1 µM) for an additional 24 h, and the cell layer 162
was wounded with 200 µL tips. After 24 h of incubation, the cells were 163
photographed with a BZ-8100 microscope (Keyence, Japan).

164 Invasion assays

165 Cell invasiveness was assessed with a BioCoat Matrigel Invasion 166
Chamber kit according to the protocol of the manufacturer (Becton 167
Dickinson Labware, Bedford, MA). We seeded 5×10^4 Hec1-SP or 168
-NSP cells treated with or without salinomycin (1 µM) into the 169
Transwell insert chamber with a filter coated with Matrigel and placed 170
the inserts in the lower chambers filled with 750 µL of DMEM 171
containing 10% FBS. Chambers were incubated at 37 °C under a 5% 172
CO₂ atmosphere for 24 h. Thereafter, we removed the inserts and 173
scraped off the non-invading cancer cells remaining on the upper side 174
of the filter. The cells that had invaded the lower side of the filter 175
were viewed under a Nikon phase-contrast microscope and counted 176
in > 10 fields of view at $\times 200$ magnification. The number of cells on 177
the lower side of the filter was normalized to cells using the control 178
chamber without matrigel. The assay was done in triplicate.

179 In vivo tumor formation assay

180 We inoculated 1×10^5 cells in Matrigel (BD Matrigel Basement 181
Membrane Matrix High Concentration; BD Biosciences, Bedford, MA) 182
into the subcutaneous connective tissue of five-week-old nude mice 183
(Balb nu/nu). Four to six months after injection of Hec1-SP cells, mice 184
were sacrificed and the tumors excised. Eight mice were injected subcu- 185
taneously with 0.26 µM salinomycin and another eight mice were 186
injected with 100 1/4 L DMSO twice a week. The size of the tumor 186 Q3


187 was measured every week. The weight of each mouse was recorded
 188 once a week. Blood was taken from the mice with a syringe, which
 189 was flushed with heparin before blood withdrawal. All mouse experi-
 190 ments were approved by the animal ethics committee of Juntendo
 191 University.

192 *TUNEL labeling*


193 The Hec1-SP and NSP cells were cultured on chamber slide (BD
 194 Falcon™), and they were fixed in 1% paraformaldehyde in PBS, PH 7.4,

for 10 min at room temperature. The cells were post-fixed in 195
 pre-cooled ethanol: acetic acid (2:1) for 5 min at -20 °C. The sections 196
 were immersed in 3% hydrogen peroxide for 10 min, and DNA 3-end la- 197
 beling of apoptotic cells was performed by the Apop-Tag Plus Peroxi- 198
 dase Kit (Oncor, Inc. Gaithersburg, MD). After washing several times 199
 in PBS and the equilibration buffer, the sections were incubated with 200
 terminal deoxynucleotidyl transferase (TdT) for 1 h in a humidified 201
 chamber at 37 °C. Subsequently, the sections were immersed in stop 202
 wash buffer for 15 min, washed in PBS and incubated in anti- 203
 digoxigenin peroxidase for 30 min, at 37 °C. After several washes in 204

A GeneGo Pathway Maps



B Development Regulation of epithelial-to-mesenchymal transition(EMT)



Q2

Fig. 1. EMT and the phenotype of endometrial CSCs. We used the Metacore package to identify the Gene GO pathway MAPs involved in upregulated genes in the microarray data on a set of K12V-SP cells and -NSP cells. A) Four Gene GO pathways of EMT were involved in the top ten scoring pathways. B) Nine genes were included in a total of 64 genes involved in the development regulation of EMT.

PBS, the reaction was revealed by DAB (3,3'-diaminobenzidine tetrahydrochloride) and finally, the sections were counterstained with Mayer's hematoxylin. Negative controls were processed in the same manner, except that TdT was replaced with distilled water. Moreover, involuting mammary gland sections (provided by Apop-Tag Kit/Oncor, Inc. Gaithersburg) were used as positive controls for the TUNEL method. The sections were examined and photographed with an OLYMPUS BX-50.

213 Microarray

214 Total RNA was extracted using RNeasy Mini Kits according to the
215 manufacturer's instructions (QIAGEN). Microarray analysis was
216 performed by Takara Bio customer service. Briefly, cDNAs were syn-
217 thesized by GeneChip T7-Oligo (dT) Promoter Primer Kit (Affymetrix)
218 and TaKaRa cDNA Synthesis Kit (TaKaRa Bio) from 5 µg total RNA.
219 Biotinylated cDNAs were synthesized with the IVT Labeling Kit
220 (Affymetrix). Following fragmentation, 10 µg of cDNA were hybrid-
221 ized for 16 h at 45 °C on GeneChip Rat Genome 230 2.0 Array.
222 GeneChips were scanned using a GeneChip Scanner 3000. Single
223 Array Analysis was calculated by Microarray Suite version 5.0
224 (MAS5.0) with Affymetrix default settings.

225 Pathway analysis

226 Genetic pathways were evaluated using the MetaCore Analytical
227 Suite (Gene Go Inc.). Enrichment analysis consisted of mapping
228 gene IDs of the dataset onto IDs in entities of built-in functional ontol-
229 ogies represented in MetaCore by pathway maps and networks.

230 Data analysis

231 Data are represented as the means ± SEM and were analyzed
232 with Student's *t*-test. For all analyses, two-sided tests of significance
233 were used, with $p < 0.05$ considered significant.

234 Results

235 EMT: an important characteristic of endometrial CSCs

236 We previously demonstrated that both Hec1-SP cells and RK12V-SP
237 cells have features of CSCs [8,14]. We found that the quality of mRNA
238 derived from RK12V-SP cells isolated by flow cytometry was better
239 than that from Hec1-SP cells. Thus, we performed microarray expres-
240 sion analysis to screen for up-regulated genes in CSCs on a set of
241 RK12V-SP cells and -non-SP (NSP) cells. We identified 450 genes that
242 were up-regulated more than two-fold in RK12V-SP cells compared
243 with those in RK12V-NSP cells. The top 50 genes are shown in Supple-
244 mentary Table 2. We used the Metacore package to identify the Gene
245 GO pathway MAPs involved in the upregulated genes in RK12V-SP
246 cells. The gene map with the highest P value (7.97×10^{-8}) was "De-
247 velopmental Regulation of EMT" and nine genes were included out of
248 a total of 64 genes of this pathway (Fig. 1A, B). Four Gene GO pathways
249 of EMT were involved in the top ten scoring pathways (Fig. 1A). In
250 agreement with the previous study by Mani et al., the microarray
251 data on a set of RK12V-SP cells and -NSP cells showed that the path-
252 ways associated with EMT were important characteristics of endome-
253 trial CSCs [10].

254 The levels of EMT-associated genes were enhanced in Hec1-SP cells

255 We subjected Hec1-SP cells to real time PCR to analyze the levels
256 of several types of EMT-associated genes that were enhanced in
257 breast CSCs as shown by Mani et al. [10] and compared the results
258 with those in Hec1-NSP cells. As expected, the expression levels of
259 CD9, which is a glandular marker, in Hec1-SP cells were reduced

($p < 0.01$). In contrast, the levels of EMT-associated genes were in- 260
261 creased. In particular, the level of *fibronectin* expression was signifi-
262 cantly enhanced in Hec1-SP cells compared with that in Hec1-NSP
263 cells (Fig. 2). These results demonstrated that EMT processes are oc-
264 ccurring in Hec1-SP cells as well as in RK12V-SP cells.

Salinomycin inhibited the proliferation of Hec1-SP cells

265 Next, we examined the effect of salinomycin (a compound with 266
267 EMT-specific toxicity) on the proliferation of Hec1-SP cells and
268 Hec1-NSP cells. We assessed the viability of Hec1-SP cells and
269 Hec1-NSP cells in the presence or absence of salinomycin (0.1, 1.0
270 and 5.0 µM) for 72 h. Proliferation of Hec1-NSP cells was inhibited
271 at all of these concentrations. The viability of Hec1-SP cells was
272 suppressed by treatment with concentrations of salinomycin more
273 than 1 µM (Fig. 3A). Chromatin fragmentation was observed in
274 Hec1-SP cells treated with 1 µM salinomycin, suggesting that apo-
275 ptosis was induced (Fig. 3B). We confirmed apoptotic cells by
276 TUNEL staining and SP cells treated with 1 µM salinomycin
277 contained more apoptotic cells than non-treated SP cells (Fig. 3C).
278 Salinomycin inhibited the proliferation of RK12V-SP cells as well as
279 Hec1-SP cells (Fig. 3A).

Salinomycin induced apoptosis and inhibited Wnt signaling

280 To examine the induction of apoptosis by salinomycin in Hec1-SP 281
282 cells and Hec1-NSP cells, we evaluated the expression of *BAX* and
283 *BCL2* by real time PCR. The expression of *BAX*, a pro-apoptotic protein,
284 was increased although it was not significantly different, and that of
285 *BCL2*, an anti-apoptotic protein, was suppressed by treatment with
286 1 µM salinomycin significantly (Fig. 4A).

287 A recent study demonstrated that salinomycin downregulated the
288 expression of Wnt target genes such as *LEF1*, *cyclin D1*, and *fibronectin*
289 [15]. Thus, we assessed the expression of *LEF1* and *cyclin D1* by real
290 time PCR. A gradual decrease of *LEF1* and *cyclin D1* expression was ob-
291 served during treatment with salinomycin (Fig. 4B).

Salinomycin suppressed fibronectin expression and inhibited migration and invasion of Hec1-SP cells

292 We evaluated the level of *fibronectin* expression in Hec1-SP cells 294
295 and Hec1-NSP cells in the presence or absence of salinomycin. The




Fig. 2. The levels of EMT-associated genes were enhanced in Hec1-SP cells. We subjected Hec1-SP cells to real time PCR to analyze the levels of several types of EMT-associated genes and compared the results with those in Hec1-NSP cells. The expression levels of CD9, which is a glandular marker, in Hec1-SP cells were reduced ($p < 0.01$). In contrast, the levels of EMT-associated genes were increased. In particular, the level of *fibronectin* expression was significantly enhanced in Hec1-SP cells compared with that in Hec1-NSP cells.

296 level of *fibronectin* was reduced in Hec1-SP cells treated with 1 μM
 297 salinomycin (Fig. 5A).

298 We previously demonstrated that Hec1-SP cells showed prominent
 299 migration activity. Thus, we investigated the effect of salinomycin on
 300 migration of Hec1-SP cells by time-lapse videomicroscopy. Migration of
 301 Hec1-SP cells was gradually inhibited by treatment with 1 μM
 302 salinomycin and completely suppressed after 16 h of treatment (Sup-
 303 plementary Fig. 1).

304 Next, we analyzed cell migration activity using the in vitro scratch
 305 assay. Migration of Hec1 and RK12V-SP cells was enhanced compared
 306 with that of Hec1 and RK12V-NSP cells. Enhanced migration of these
 307 SP cells was completely suppressed by treatment with 1 μM
 308 salinomycin for 24 h (Fig. 5B). We also examined cell invasiveness
 309 using the Boyden chamber assay with a filter coated with Matrigel.
 310 The invasiveness of Hec1 and RK12V-SP cells was enhanced compar-
 311 ed with that of Hec1 and RK12V-NSP cells. Enhanced migration of

these SP cells was significantly suppressed by treatment with 1 μM
 salinomycin for 24 h (Fig. 5C).

Salinomycin inhibited the tumorigenicity of Hec1-SP cells 314

315 Finally, we investigated the effect of salinomycin on the tumorigene-
 316 nicity of Hec1-SP cells in vivo. Hec1-SP cells (1×10^5) were inoculat-
 317 ed into the subcutaneous tissue of nude mice. After palpable tumors
 318 (1 cm^3) had developed, we injected 0.26 μM of salinomycin or
 319 DMSO directly into the tumors. Tumors in DMSO-treated mice contin-
 320 ued to grow. In contrast, tumors in salinomycin-treated mice stopped
 321 growing. In fact, tumor size in salinomycin-treated mice was reduced
 322 compared with tumors in DMSO-treated mice (Fig. 6). Primary cultur-
 323 ed cells derived from tumors of salinomycin-treated mice did not
 324 form colonies. Finally, we evaluated the toxicity of salinomycin. No
 325 hematologic toxicity was observed except for elevation of K^+ .




Fig. 3. Salinomycin inhibited proliferation of Hec1-SP cells. A) We assessed the viability of Hec1 and RK12V-SP cells and Hec1 and RK12V-NSP cells in the presence or absence of salinomycin (0.1, 1.0, and 5.0 μM) for 72 h. Viability of these-SP cells was suppressed by treatment with more than 1.0 μM salinomycin. B) Chromatin fragmentation was observed in Hec1-SP cells treated with 1.0 μM salinomycin, suggesting that apoptosis was induced. C) Tunnel labeling of apoptotic cells was performed by the Apop-Tag Plus Peroxidase Kit. SP cells treated with one μM salinomycin contained more apoptotic cells than non-treated SP cells.




Fig. 4. Salinomycin induced apoptosis and inhibited Wnt signaling. A) The expressions of *BAX* and *BCL2* were investigated by real-time PCR. The expression of *BAX*, a pro-apoptotic protein was increased although it was not significantly different, and the expression of *BCL2*, an anti-apoptotic protein was suppressed by treatment with 1 μ M salinomycin significantly. B) The expression of *LEF1* and *cyclin D1* was investigated by real-time PCR. A gradual decrease of *LEF1* and *cyclin D1* expression was caused by treatment with salinomycin.

326 Elevated K^+ was also seen in DMSO-treated mice and control mice
 327 (non-treated mice). Therefore, we suspect that the change in K^+
 328 was not associated with salinomycin (Supplementary Table 3).

329 Discussion

330 Previous studies have shown that CSCs are resistant to chemo- or
 331 radio-therapy [7,16–18]. Current cancer treatment may fail to elimi-
 332 nate CSCs and surviving CSCs can regenerate new tumors, leading to
 333 relapse and metastasis. Mani et al. showed that EMT in normal or
 334 neoplastic mammary epithelial cell populations results in the enrich-
 335 ment of stem-like cells [10]. Gupta et al. demonstrated that normal
 336 and cancer cell populations engaged in the EMT process exhibit in-
 337 creased resistance to chemotherapy. These data suggests that EMT
 338 is associated with the resistance to cancer therapy, and may be linked
 339 to relapse or metastasis [11].

340 We showed in the present study that fibronectin is overexpressed in
 341 Hec1-SP cells compared with Hec1-NSP cells. Fibronectin is an extracel-
 342 lular matrix (ECM) ligand. Cell adhesion to the ECM initiates signaling
 343 cascades regulated by cell surface integrin receptors, affecting the pro-
 344 liferation and invasiveness of cells. The interaction of fibronectin with
 345 $\alpha 5 \beta 1$ integrin leads to integrin activation that is critical for cell survival
 346 and proliferation [19]. Recent evidence has shown that fibronectin is

also associated with resistance to cancer therapy in breast cancer cells,
 leukemic cells and prostate cancer cells [20–22]. Amudson et al. have
 reported that fibronectin 1 is a potent predictor of radiation resistance
 in head and neck cancer [23]. It is likely that enhancement of fibronectin
 levels in Hec1-SP cells contributes to the properties of CSC, including
 EMT or chemo-resistance in endometrial cancer.

In 2009, Gupta et al. developed a new, high throughput screening
 method to search for compounds that attack CSCs [11]. Of 16,000 dif-
 ferent chemicals that were tested, only a small number of substances
 (salinomycin, etoposide, abamectin and nigericin) showed selective
 toxicity for breast cancer stem cells. Among them, salinomycin was
 the most selective inhibitor of CSCs. Since then, several studies have
 shown that salinomycin has an inhibitory effect on cell proliferation
 in human cancer cells [24–26].

Salinomycin is a 751 Da monocarboxylic polyether antibiotic that
 consists of a large pentacyclic molecule with a unique tricyclic spiroketal
 ring system and an unsaturated six membered ring. Salinomycin acts in
 cytoplasmic and mitochondrial membranes as an ionophore with strict
 selectivity for alkali ions and a strong preference for potassium, thereby
 promoting mitochondrial and cellular potassium efflux and inhibiting mi-
 tochondrial oxidative phosphorylation. Salinomycin has been used as an
 anti-coccidial drug in poultry and is fed to cattle to increase their size
 [27]. Recent studies demonstrated that salinomycin induces apoptosis




Fig. 5. Salinomycin suppressed *fibronectin* expression and inhibited migration and invasion of Hec1-SP cells. A) The level of *fibronectin* expression was investigated in Hec1-SP cells and Hec1-NSP cells in the presence or absence of salinomycin. The level of *fibronectin* was reduced in Hec1-SP cells treated with 1.0 μM salinomycin. B) Cell migration activity was investigated with the in vitro scratch assay. Migration of Hec1 and RK12V-SP cells was enhanced compared with that of Hec1 and RK12V-NSP cells. Enhanced migration of Hec1 and RK12V-SP cells was completely suppressed by the treatment with 1 μM salinomycin for 24 h. C) Cell invasion activity was examined with the Boyden chamber assay with a filter coated with Matrigel. Invasion of Hec1 and RK12V-SP cells was enhanced compared with that of Hec1 and RK12V-NSP cells. Enhanced migration of Hec1-SP and RK12V-NSP cells was significantly suppressed by treatment with 1 μM salinomycin for 24 h.

370 and overcomes apoptosis resistance by overexpression of Bcl-2, P-
 371 glycoprotein or 26S proteasomes with deregulated proteolytic activity
 372 in human cancer cells of different origins [25,26,28]. Furthermore,
 373 salinomycin overcomes multidrug resistance in CSCs that express
 374 ATP-binding cassette (ABC) transporters capable of removing chemo-
 375 therapeutic drugs from the cytosol. Salinomycin sensitizes cancer cells
 376 to the effects of chemotherapy or radiation treatment by increasing
 377 DNA damage [26]. Fuchs et al. demonstrated that salinomycin induced
 378 massive apoptosis in CD4 + T cell leukemia and failed to induce apoptosis
 379 in normal CD4+T cell. These results suggest that salinomycin kills
 380 apoptosis-resistant cancer cells, but not normal cells [24].

381 Salinomycin effectively kills not only cancer cells but also cancer
 382 stem cells from different origins displaying ABC transporter-mediated
 383 multidrug resistance [24,29]. Dong et al. reported that salinomycin re-
 384 duces the proportion of CD133⁺ cell subpopulations in human colorec-
 385 tal cancers cell lines (CRC) and down-regulates the expression of
 386 vimentin and induces E-cadherin expression in CRC cell lines [30].

Lu et al. reported that salinomycin downregulated the expression 387
 of Wnt target genes such as *LEF1*, *cyclin D1*, and *fibronectin*. Moreover, 388
 normal human peripheral blood lymphocytes resisted salinomycin 389
 toxicity [15]. We also demonstrated in the present study that 390
 salinomycin suppressed the level of fibronectin and inhibited prolifer- 391
 ation, migration and invasion of endometrial CSCs (Hec1 and 392
 RK12V-SP cells). Salinomycin would likely be an effective anticancer 393
 agent for endometrial CSCs. 394

Salinomycin is widely used as an antibiotic for domestic animals, 395
 however, use of salinomycin has not reached the human trial stage. In 396
 China, a group accidentally ingested high levels of salinomycin during 397
 a banquet due to the mistaken substitution of salinomycin powder for 398
 starch. Symptoms included dizziness, nausea, vomiting, stomach ache, 399
 diarrhea, limb anesthesia, weakness, and red to brown urine [31]. It is 400
 necessary to examine salinomycin dosage carefully to determine 401
 human toxicity and to develop new derivatives of salinomycin with re- 402
 duced toxicity for human clinical applications. 403




Fig. 6. Salinomycin inhibited tumorigenicity of Hec1-SP cells. The effect of salinomycin on tumorigenicity of Hec1-SP cells *in vivo*. Hec1-SP cells (1×10^5) were inoculated into the subcutaneous tissue of nude mice. When palpable tumors (1 cm^3) developed, we injected $0.26 \mu\text{M}$ or DMSO directly into tumors. Tumor size in salinomycin-treated mice ($n = 5$) was reduced compared with tumors in DMSO-treated mice ($n = 6$).

In this study, we demonstrated that i) EMT processes were underway in both RK12V-SP cells and Hec1-SP cells, ii) the level of fibronectin was enhanced in Hec1-SP cells and salinomycin reduced the level of fibronectin expression, and iii) salinomycin induced apoptosis and inhibited proliferation, migration, invasion and tumorigenicity in these SP cells. This is the first report of an inhibitory effect of salinomycin on the properties of endometrial CSCs.

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.ygyno.2013.03.005>.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

- [1] Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 1997;3:730–7.
- [2] Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994;367:645–8.
- [3] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003;100:3983–8.
- [4] Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. *Nat Rev Cancer* 2006;6:425–36.
- [5] Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating *in vivo*. *J Exp Med* 1996;183:1797–806.
- [6] Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* 2001;7:1028–34.
- [7] Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer* 2005;5:275–84.
- [8] Kato K, Takao T, Kuboyama A, Tanaka Y, Ohgami T, Yamaguchi S, et al. Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage. *Am J Pathol* 2010;176:381–92.

- [9] Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. *J Clin Invest* 2009;119:1420–8.
- [10] Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. *Cell* 2008;133:704–15.
- [11] Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* 2009;138:645–59.
- [12] Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma *in vitro*. *Am J Obstet Gynecol* 1972;114:1012–9.
- [13] Wiehle RD, Helftenbein G, Land H, Neumann K, Beato M. Establishment of rat endometrial cell lines by retroviral mediated transfer of immortalizing and transforming oncogenes. *Oncogene* 1990;5:787–94.
- [14] Kato K, Kuhara A, Yoneda T, Inoue T, Takao T, Ohgami T, et al. Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. *Mol Cancer Ther* 2011;10:1430–9.
- [15] Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. *Proc Natl Acad Sci U S A* 2011;108:13253–7.
- [16] Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 2006;444:756–60.
- [17] Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. *J Clin Oncol* 2008;26:2839–45.
- [18] Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. *Nature* 2009;458:780–3.
- [19] Sil H, Sen T, Chatterjee A. Fibronectin-integrin (alpha5beta1) modulates migration and invasion of murine melanoma cell line B16F10 by involving MMP-9. *Oncol Res* 2011;19:335–48.
- [20] Thomas F, Holly JM, Persad R, Bahl A, Perks CM. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. *Prostate* 2010;70:856–65.
- [21] Pontiggia O, Sampayo R, Raffo D, Motter A, Xu R, Bissell MJ, et al. The tumor micro-environment modulates tamoxifen resistance in breast cancer: a role for soluble stromal factors and fibronectin through beta1 integrin. *Cancer Res Res Ther* 2012;133:459–71.
- [22] De Toni-Costes F, Despeaux M, Bertrand J, Bouroga E, Ysebaert L, Payrastré B, et al. A new alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. *PLoS One* 2010;5:e9807.
- [23] Amundson SA, Smilenov LB. Integration of biological knowledge and gene expression data for biomarker selection: FN1 as a potential predictor of radiation resistance in head and neck cancer. *Cancer Biol Ther* 2011;10:1252–5.
- [24] Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. *Biochem Biophys Res Commun* 2010;394:1098–104.
- [25] Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. *Biochem Biophys Res Commun* 2011;413:80–6.
- [26] Kim JH, Yoo HI, Kang HS, Ro J, Yoon S. Salinomycin sensitizes antimetabolic drug-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. *Biochem Biophys Res Commun* 2012;418:98–103.
- [27] Mitani M, Yamanishi T, Miyazaki Y. Salinomycin: a new monovalent cation ionophore. *Biochem Biophys Res Commun* 1975;66:1231–6.
- [28] Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. *Biochem Biophys Res Commun* 2009;390:743–9.
- [29] Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. *Blood Cells Mol Dis* 2010;45:86–92.
- [30] Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. *Ann Surg Oncol* 2011;18:1797–804.
- [31] Li Y, Fang J, Wu S, Ma K, Li H, Yan X, et al. Identification and quantification of salinomycin in intoxicated human plasma by liquid chromatography–electrospray tandem mass spectrometry. *Anal Bioanal Chem* 2010;398:955–61.